Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCC NASDAQ:EDSA NASDAQ:LSB NASDAQ:PWUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$8.23+5.2%$8.07$3.08▼$597.60$18.44M0.08201,338 shs96,729 shsEDSAEdesa Biotech$2.36-1.3%$2.22$1.55▼$5.00$16.82M0.2722,033 shs665 shsLSBLakeShore Biopharma$0.83+3.3%$0.93$0.59▼$8.60$16.61M0.5647,720 shs8,881 shsPWUPPowerUp Acquisition$0.56+4.5%$0.38$8.05▼$15.80$71.75M0.053,464 shs1.81 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals+5.24%+3.00%-33.58%-66.73%-96.97%EDSAEdesa Biotech-3.83%-1.67%+3.74%+18.00%-46.85%LSBLakeShore Biopharma+3.25%-0.36%+9.38%-22.80%-81.31%PWUPPowerUp Acquisition+4.47%+3.61%+15.72%+29.41%-95.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals1.1241 of 5 stars0.04.00.00.02.72.50.0EDSAEdesa Biotech2.1671 of 5 stars2.05.00.00.03.31.70.6LSBLakeShore Biopharma1.1419 of 5 stars0.05.00.00.02.20.80.6PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AEDSAEdesa Biotech 4.00Strong Buy$5.00111.86% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/APWUPPowerUp Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PWUP, EDSA, LSB, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$10K1,842.70N/AN/A$1.62 per share5.08EDSAEdesa BiotechN/AN/AN/AN/A$0.70 per shareN/ALSBLakeShore Biopharma$85.67M0.20N/AN/A$3.35 per share0.25PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-723.64%-145.51%11/10/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.32N/AN/AN/AN/A-162.95%-60.33%N/ALSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest PWUP, EDSA, LSB, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A8/8/2025Q3 2025EDSAEdesa Biotech-$0.26-$0.25+$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel Pharmaceuticals$0.151.82%N/AN/A N/AEDSAEdesa BiotechN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.775.77EDSAEdesa BiotechN/A18.9618.96LSBLakeShore Biopharma0.051.020.75PWUPPowerUp AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%EDSAEdesa Biotech5.50%LSBLakeShore Biopharma52.64%PWUPPowerUp Acquisition19.17%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals51.20%EDSAEdesa Biotech22.60%LSBLakeShore BiopharmaN/APWUPPowerUp Acquisition48.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionableEDSAEdesa Biotech207.04 million5.45 millionNot OptionableLSBLakeShore Biopharma77320.77 millionN/AN/APWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionablePWUP, EDSA, LSB, and CYCC HeadlinesRecent News About These CompaniesAspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | finanznachrichten.deAspire Biopharma, PowerUp Acquisition complete business combinationFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma announces public listing on NasdaqFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | accessnewswire.comAAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 19, 2025 | accessnewswire.comA(PWUP) Technical Pivots with Risk ControlsFebruary 13, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp trading resumesFebruary 12, 2025 | markets.businessinsider.comPowerUp Acquisition Corp trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPowerUp Stock Soars to All-Time High of $14.84 Amidst Strong GrowthFebruary 11, 2025 | msn.comPowerUp Acquisition Corp. Approves Merger with Aspire BiopharmaFebruary 11, 2025 | msn.comWhen (PWUP) Moves Investors should ListenFebruary 2, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp. Cl AJanuary 17, 2025 | wsj.comHow to Take Advantage of moves in (PWUP)January 12, 2025 | news.stocktradersdaily.comNPWUP PowerUp Acquisition Corp.December 12, 2024 | seekingalpha.comHow To Trade (PWUP)November 19, 2024 | news.stocktradersdaily.comNWhen the Price of (PWUP) Talks, People ListenOctober 18, 2024 | news.stocktradersdaily.comNSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGROctober 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of ShareholdersOctober 8, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGROctober 7, 2024 | accesswire.comA(PWUPU) Investment AnalysisSeptember 26, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimePWUP, EDSA, LSB, and CYCC Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$8.23 +0.41 (+5.24%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.02 -0.22 (-2.61%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Edesa Biotech NASDAQ:EDSA$2.36 -0.03 (-1.26%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$2.31 -0.05 (-2.33%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.LakeShore Biopharma NASDAQ:LSB$0.83 +0.03 (+3.25%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.PowerUp Acquisition NASDAQ:PWUP$0.56 +0.02 (+4.47%) As of 08/28/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
